Biogen acquires neuromuscular assets, reports 2Q earnings

Biogen Inc. (NASDAQ:BIIB) said it acquired two early stage neuromuscular assets from AliveGen USA Inc. (Thousand Oaks, Calif.) and reported rising U.S. sales of spinal muscular atrophy (SMA) therapy Spinraza

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE